Large‐scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*
British Journal of Dermatology, 2021
Navrazhina K., Renert‐Yuval Y., Frew J., Grand D., Gonzalez J., Williams S., Garcet S., Krueger J.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Dermatological Diseases | Patient Stratification | Serum |  Olink Explore 3072/384 |
Abstract
Background
Hidradenitis Suppurativa (HS) is now recognized as a systemic inflammatory disease, sharing molecular similarities with psoriasis. Direct comparison of the systemic inflammation in HS with psoriasis is lacking.
Objectives
To evaluate the serum proteome of HS and psoriasis, and to identify biomarkers associated with disease severity.
Methods
In this cross-sectional study, 1,536 serum proteins were assessed using the Olink Explore (Proximity Extension Assay/PEA) high-throughput panel in moderate-to-severe HS (n=11), psoriasis (n=10) and age- and BMI-matched healthy controls (n=10).
Results
HS displayed an overall greater dysregulation of circulating proteins, with 434 differentially expressed proteins (|FCH|≥1.2, p-value≤0.05) in HS versus controls, 138 in psoriasis versus controls, and 503 between HS and psoriasis. IL-17A levels and Th1/Th17 pathway enrichment were comparable between diseases, while HS presented greater TNF and IL-1β-related signaling. Th17-associated markers, PI3 and LCN2, were able to accurately differentiate psoriasis from HS. Both diseases presented increases of atherosclerosis-related proteins. Robust correlations between clinical severity scores and immune and atherosclerosis-related proteins were observed across both diseases.
Conclusions
HS and psoriasis share significant Th1/Th17 enrichment and upregulation of atherosclerosis-related proteins. Nevertheless, despite the greater body surface area involved in psoriasis, HS presents a greater serum inflammatory burden.